Clinical Trials Browser

Recruiting × Pancreatic Neoplasms × Bevacizumab × Clear all

NCT05005403 2026-04-13

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

BreastGastrointestinalHead & NeckThoracic

Anophthalmia with pulmonary hypoplasia, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT06445062 2026-04-01

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Phase 1/2 Recruiting

1,130 enrolled

Gastrointestinal

Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT06400472 2026-01-14

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

Phase 1 Recruiting

495 enrolled

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06313970 2025-09-03

First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients

Phase 2 Recruiting

58 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06229340 2024-01-29

NТО-RAS

Phase 2 Recruiting

20 enrolled

DermatologicGastrointestinalThoracic

Lung Neoplasms, Melanoma, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms